

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques



Eric Ambrose Linell — In Memoriam T.P. Morley 159

ORIGINAL ARTICLES

Acute Spinal Cord Injury in the Rat: Comparison of Three Experimental Techniques Moe Khan and Robert Griebel 161

C.T. Aided Stereotaxy for Depth Electrode Implantation and Biopsy T.M. Peters and André Olivier 166

Mitochondrial Myopathy of Cerebro-Hepato-Renal (Zellweger) Syndrome Harvey B. Sarnat, Geoffrey Machin, Huzam Z. Darwish and Steven Z. Rubin 170

Evaluation of Radiculopathies by Segmental Stimulation and Somatosensory Evoked Potentials Andrew Eisen, Maureen Hoirch and Alex Moll 178

Delayed Auditory Tone Perception in Multiple Sclerosis Douglas B. Quine, David Regan and Thomas J. Murray 183

Hemifacial Spasm: Results of Microvascular Relocation David Fairholm, Jiunn-Ming Wu and Kan-Nan Liu 187

Intradural Rupture of Lumbar Intervertebral Disc Shih-Tseng Lee and David Fairholm 192

Kinetics of CSF Phenytoin in Children G. Koren, Z. Barzilay, E. Schachar, N. Brand, S. Daneq, H. Halkin and S.M. MacLeod 195

EEG Abnormalities and Convulsions in Juvenile Diabetes Mellitus D.L. Keene, K. Metrakos, M. Belmonte, G.V. Watters and S. Singer 198

Infantile Huntington's Disease R.H.A. Haslam, B. Curry and R. Johns 200

Paraneoplastic Subacute Necrotic Myelopathy Adrian Handforth, Sukriti Nag, Daniel Sharp and David M. Robertson 204

HISTORICAL PERSPECTIVE

The Discovery, Proof and Reproof of Neurosecretion Harvey B. Sarnat 208


BOOK REVIEWS 213

NOTES AND ANNOUNCEMENTS 215

The Official Journal of

- The Canadian Neurological Society
- The Canadian Neurosurgical Society
- The Canadian Society of Clinical Neurophysiologists
- The Canadian Association for Child Neurology

you wouldn't guess Jane's an epileptic



Epileptic therapy doesn't have to interfere with her life. Depakene can effectively control seizures, with little risk of disturbed behaviour or poor performance.

Depakene provides broad-spectrum seizure control Depakene is considered a drug of first choice for simple and complex absence seizures^{1,2} and has been successfully used in tonic-clonic or myoclonic seizures with absence components.^{3,4}

No impairment of learning Depakene has made patients more alert, more lively and better able to perform daily tasks.⁵

Positive effect on behaviour Depakene, unlike phenobarbital, rarely affects behaviour, and may actually improve it.⁵

Low incidence of disturbing side effects Depakene does not cause hirsutism, gum hyperplasia or acne, nor has it been associated with aplastic anemia or agranulocytopenia.

Minimizes problems of polypharmacy Depakene is often effective as single therapy. When other anticonvulsants are necessary, their dosage may be reduced.

New dosage convenience A 500-mg enteric-coated capsule is now available.

valproic acid
Depakene^{*}
brings many epileptic patients closer to normal

 PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
MONTREAL, CANADA H4P 1A5

See page x

*TM  

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

Editor

Robert G. Lee
Calgary

Associate Editor

André Barbeau
Montreal

Founding Editor

Robert T. Ross
Winnipeg

Editorial Board

Albert J. Aguayo
Montreal

Henry J.M. Barnett
London

Paul Bédard
Quebec

Henry B. Dinsdale
Kingston

Guy Geoffroy
Montreal

Alan Hudson
Toronto

Yves Lamarre
Montreal

Bernard Lemieux
Sherbrooke

William J. Logan
Toronto

Morton Low
Vancouver

Thomas P. Morley
Toronto

Thomas J. Murray
Halifax

Donald Paty
Vancouver

Sidney J. Peerless
London

Terry Picton
Ottawa

Jean Reiher
Sherbrooke

Leo P. Renaud
Montreal

Barry Rewcastle
Calgary

Matthew W. Spence
Halifax

William G. Tatton
Toronto

Bryce Weir
Edmonton

Book Review Editor

T. Peter Seland
Calgary

Editorial Assistant

Sally Gregg
Calgary

THE EDITORIAL BOARD wishes to publish original work in the basic and clinical neurosciences on the understanding that it has not been and will not be published elsewhere. Review articles on timely subjects will be accepted. Manuscripts must be in triplicate including illustrations. One of the copies must be the original, ribbon copy. Manuscripts should be typed double spaced, on white paper.

Papers will be accepted in French or English. All papers should be accompanied by a short résumé in both languages. The résumé translation will be done by the editorial board if requested.

Papers should be identified only by the full name of the author, or authors, and the name of the place in which the work was done.

ILLUSTRATIONS: Photographs should be unmounted on glossy paper and show magnification scale. They should be marked on the back with figure number, title of paper and name of author.

Diagrams should be in India ink and large enough to be informative after reduction.

All illustrations should be referred to as figures, numbered consecutively, not included in the body of the text and all captions

should be typed on a separate piece of paper.

Colored illustrations cannot usually be accepted unless the author is prepared to assist with the cost of reproduction.

REFERENCES to authors outside the context of the sentence should read (Name, Year). i.e. "However, a recent study (Bird and Iverson, 1975) showed a decreased, etc." Authors mentioned within the context of the sentence should read Name (Year), "i.e. . . . twenty years since Ecker and Reimshender (1951) demonstrated, etc." References should be typed in alphabetical order on a separate sheet and include author's name, initials, year, title, publication, volume first and last page, i.e. Isaacson, P. (1967). Myx-oviruses and autoimmunity. *Progress in Allergy*, 10, 256-292. Abbreviations should be the same as those used in Cumulated Index Medicus.

Textbook references should include name of text, author's name, page number, publisher and city.

REPRINTS: Fifty reprints will be supplied free if ordered when the galley proofs are returned. More may be ordered at a nominal charge. Corrections and changes in the galley proofs, apart from printer's errors may be charged to the author.

This journal is indexed by **Index Medicus**, **Excerpta Medica** and **Current Contents — Clinical Practice and Life Science**.

SUBSCRIPTIONS: This journal is issued four times a year. The annual rate is \$40.00 for Canada and the U.S.A. \$44.00 elsewhere. Internes, Residents, Pre- and Post-Doctoral Students, \$20.00 per annum. Single copies \$12.00 each.

ADVERTISING: Enquiries regarding advertising space and rates should be directed to LEX LTD. VANCO PUBLICATIONS, 431 Alden Road, Markham, Ontario L3R 3L4. Telephone — (416) 477-2030.

All communications, manuscripts, subscriptions, etc., should be sent to the Editor, Canadian Journal of Neurological Sciences, Faculty of Medicine, 2500 University Drive, Calgary, Alberta, Canada T2N 1N4.

COPYRIGHT © 1983 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. ISSN 0317-1671.

Published in conjunction with the University of Calgary Press.

Printed by McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5
Mailed under second class registration number 3307. Postage paid at Calgary, Alberta.

PUBLICATIONS COMMITTEE

Donald Baxter
Montreal

Andrew Eisen
Vancouver

Terry Myles
Calgary

CANADIAN NEUROLOGICAL SOCIETY

President
Past-President
Vice-President
Secretary-Treasurer

Thomas J. Murray
Henry B. Dinsdale
Robert F. Nelson
Garth M. Bray
1650 Cedar Avenue
Montreal, P.Q.
H3G 1A4

Council:
Monique Lefebvre-d'Amour
Jean Pierre Bouchard
William McCormick
Donald Calne
Ali Rajput
Peter Seland

CANADIAN NEUROSURGICAL SOCIETY

President
Past-President
President-Elect
Secretary-Treasurer

Stuart Huestis
Jules Hardy
Leslie Ivan
Gary Ferguson
University Hospital
London, Ontario
N6A 5A5

Council:
Jacques Boucher
Derek Fewer
Robin Humphreys
Fala Maroun
Andre Olivier
Barry Purves

CANADIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGISTS

President
Past-President
Secretary-Treasurer

Warren Blume
Andrew Eisen
Terry Picton
Ottawa General Hospital
501 Chemin Smythe Road
Ottawa K1H 8L6

Council:
Roger Broughton
Reda El-Sawy
Normand Giard
Leroy Heffernan
Sherrill Purves

CANADIAN ASSOCIATION FOR CHILD NEUROLOGY

President
Past President
Vice-President
Secretary-Treasurer

Rosalind Curtis
Warren Blume
Fred Andermann
Jean Gibson
I.W. Killam Hospital
P.O. Box 3070
Halifax, Nova Scotia B3J 3G9

Council:
Peter Camfield
Shashikant Seshia
Simon Verrett



Lioresal[®]
baclofen



Traitez la spasticité dès le début pour accélérer son rétablissement.

Une prompt intervention avec le Lioresal, avant qu'une incapacité majeure ne s'installe, peut grandement contribuer à la réadaptation!

- Lioresal aide à soulager la spasticité due aux lésions de la moelle épinière, à la sclérose en plaques et autres affections médullaires.
- Lioresal agit principalement au niveau de la moelle épinière éliminant le risque de sédation excessive gênante.²
- Lioresal améliore la perspective d'un traitement prolongé!

Lioresal[®]...

avant qu'il ne soit trop tard.

Brief Prescribing Information

Tegretol® No substitution.

200 mg carbamazepine

Indications and clinical use

a) *Trigeminal Neuralgia:*

Tegretol is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). It should not be used preventively during periods of remission. In some patients, Tegretol has relieved glossopharyngeal neuralgia. For patients who fail to respond to Tegretol, or who are sensitive to the drug, recourse to other accepted measures must be considered. Tegretol is not a simple analgesic and should not be used to relieve trivial facial pains or headaches.

b) *Tegretol has been found useful:*

1. in the management of psychomotor (temporal lobe) epilepsy and,
2. as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication.
3. as an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs.

Tegretol is essentially ineffective in controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent the generalization of epileptic discharge.

Contraindications

Tegretol should not be administered to patients with a history of hepatic disease or serious blood disorder.

Tegretol should not be administered immediately before, in conjunction with, or immediately after a monoamine oxidase inhibitor. When it seems desirable to administer Tegretol to a patient who has been receiving an MAO inhibitor, there should be as long a drug-free interval as the clinical condition allows, but in no case should this be less than 14 days. Then the dosage of Tegretol should be low initially, and increased very gradually.

Tegretol should not be administered to patients presenting atrioventricular heart block.

Safe use in pregnancy has not been established. Therefore, Tegretol should not be administered during the first three months of pregnancy.

Tegretol should not be given to women of child-bearing potential unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible risk to the foetus (See Reproductive Studies). Because of demonstrated toxicity in nursing animals, Tegretol should not be administered to nursing mothers.

Because of the similarity of chemical structure, Tegretol should not be administered to patients with known hypersensitivity to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine, or their analogues or metabolites.

Warnings

Although reported infrequently, serious adverse effects have been observed during the use of Tegretol. Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia and hepatocellular and cholestatic jaundice have also been reported. It is, therefore, important that Tegretol should be used carefully and close clinical and frequent laboratory supervision should be maintained throughout treatment in order to detect as early as possible signs and symptoms of a possible blood dyscrasia.

Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore, the possible risk of drug use must be weighed against the potential benefits before prescribing carbamazepine to individual patients.

Precautions

Monitoring of Haematological and Other Adverse

Reactions: Complete blood studies, including platelet counts, and evaluation of hepatic and renal function and urinalysis should be carried out before treatment is instituted. Careful clinical and laboratory supervision should be maintained throughout treatment, including frequent performance of complete blood counts, in order to detect any early signs or symptoms or blood dyscrasia. Should any signs or symptoms or abnormal laboratory findings suggestive of blood dyscrasia or liver disorder occur, Tegretol should be immediately discontinued until the case is carefully reassessed.

Urinary Retention and Increased Intraocular Pressure: Because of its anticholinergic action, Tegretol should be given cautiously, if at all, to patients with increased intraocular pressure or urinary retention. Such patients should be followed closely while taking the drug.

Occurrence of Behavioural Disorders: Because it is closely related to the other tricyclic drugs, there is some possibility that Tegretol might activate a latent psychosis, or, in elderly patients, produce agitation or confusion, especially when combined with other drugs. Caution should also be exercised in alcoholics.

Use in Patients with Cardiovascular Disorders: Tegretol should be used cautiously in patients with a history of coronary artery disease, organic heart disease, or congestive failure. If a defective conductive system is suspected, an E.K.G. should be performed before administering Tegretol, in order to exclude patients with atrioventricular block.

Use in Patients taking Oral Contraceptives: In women under treatment with Tegretol, the reliability of oral contraceptives may be adversely affected; such patients should accordingly be advised to use some alternative, non-hormonal method of contraception.

Driving and Operating Hazardous Machinery: Because dizziness and drowsiness are possible side effects of Tegretol, patients should be warned about the possible hazards of operating machinery or driving automobiles.

Adverse Reactions

The reactions which have been most frequently reported with Tegretol are drowsiness, unsteadiness on the feet, vertigo, dizziness, gastrointestinal disturbances, and nausea. These reactions usually occur only during the initial phase of therapy. They have rarely necessitated discontinuing Tegretol therapy, and can be minimized by initiating treatment at a low dosage.

The more serious adverse reactions observed are the haematologic, hepatic, cardiovascular and dermatologic reactions, which require discontinuation of therapy.

The following adverse reactions have been reported:

Haematological reactions: Transitory leucopenia, eosinophilia, leucocytosis, thrombocytopenic purpura, agranulocytosis, macrocytic anemia and aplastic anemia. In a few instances, deaths have occurred.

Hepatic disturbances: During the long-term administration of Tegretol abnormalities in liver function tests and cholestatic or hepatocellular jaundice have been observed.

Dermatological reactions: The following reactions occurred during treatment with Tegretol: skin sensitivity reactions and rashes, erythematous rashes, pruritic eruptions, urticaria, photosensitivity, pigmentary changes, neurodermatitis and in rare cases Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, diaphoresis, erythema multiforme, erythema nodosum, and aggravation of disseminated lupus erythematosus.

Neurological reactions: The reactions reported as occurring during treatment with Tegretol include vertigo, somnolence, disturbances of coordination, confusion, headache, fatigue, blurred vision, transient diplopia and oculomotor disturbances, speech disturbances, abnormal involuntary movements and increase in motor seizures. In addition, peripheral neuritis and paresthesia, depression with agitation, talkativeness,

nystagmus, and tinnitus have been reported but only very rarely. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency but no conclusive relationship to the administration of Tegretol could be established.

Cardiovascular systems: Recurrence of thrombophlebitis in patients with a prior history of thrombophlebitis, congestive heart failure, aggravation of hypertension, Stokes-Adams in patients with AV block, hypotension, syncope and collapse, edema, aggravation of coronary artery disease. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds.

Genitourinary reactions: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, and impotence, Elevation of BUN, albuminuria and glycosuria also have been observed.

Digestive tract: Disturbances associated with Tegretol therapy have included nausea, vomiting, gastric or abdominal discomfort, diarrhoea, anorexia and dryness of the mouth and throat, glossitis and stomatitis.

Eyes: There is no conclusive evidence that Tegretol produces pathological changes in the cornea, lens or retina. However, it should be recognized that many phenothiazines and related drugs have been shown to cause eye changes. By analogy, periodic eye examinations, including slitlamp fundoscopy and tonometry, are recommended.

Other reactions reported during treatment with Tegretol include fever and chills, lymphadenopathy, aching joints and muscles, leg cramps and conjunctivitis.

Dosage and Administration

Use in Epilepsy (see Indications): A low initial daily dosage with a gradual increase in dosage is advised. Dosage should be adjusted to the needs of the individual patient.

Adults and Children over 12 years of age: Initially, 100 to 200 mg once or twice a day depending on the severity of the case and previous therapeutic history. The initial dosage is progressively increased, until the best response is obtained, up to 600 mg daily. The usual optimal dosage is 600 mg daily, but occasionally dosage up to 800 to 1000 mg have been used for short periods. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

Use in trigeminal neuralgia: The initial daily dosage should be small: 200 mg, taken in two doses of 100 mg each is recommended. The total daily dosage can be increased by 200 mg per day until relief of pain is obtained. This is usually achieved at a dosage between 200 and 800 mg daily, but occasionally up to 1200 mg per day may be necessary. As soon as relief of pain has been obtained and maintained, progressive reduction in dosage should be attempted until a minimum effective dosage is reached. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of Tegretol at intervals of not more than 3 months, depending upon the individual clinical course.

Prophylactic use of the drug in trigeminal neuralgia is not recommended.

Tegretol should be taken in two or three divided doses daily, with meals whenever possible.

Dosage Forms

Tegretol is available as a 200 mg white, round, flat bevelled edge single-scored tablet, engraved with Geigy signet.

Availability

Bottles of 50 and 500 tablets. Protect from heat and humidity.


Full information available on request.

Geigy

Mississauga, Ontario
L5N 2W5



PAAB
CCPP
G-2005

See page xiv






Neuromatic[®] 2000

*Highly Advanced
2-Channel Neuro-Myograph
for Clinical EMG and Evoked Response*



DISA — world leaders in electromyographical equipments — has created the highly advanced Neuromatic[®] 2000 for handling all electromyography measurements occurring in practice, together with evoked response examinations.

- ★ Microprocessor control of all parameters and functions
- ★ 10 investigation programs with pre-selectable settings
- ★ Patient isolated preamplifiers with high sensitivity
- ★ Impedance test of electrodes
- ★ 2-channel normalized averager
- ★ Alpha-numeric display of settings, measuring values and calculations on built-in video monitor or slave monitor
- ★ Markers for measurement of amplitude, latency and duration
- ★ Incorporates stimulators for evoked response — visual, auditory and somatosensory



DISA ELECTRONICS LTD.

140 Shorting Road, Scarborough, Ontario, M1S 3S6, Canada
Phone: (416) 298-2091 — Telex: 065-25137

SERC®

(betahistine hydrochloride tablets)

For the management of Vertigo

■ Proven efficacy

“(Serc) is now a proven, useful therapeutic agent in the treatment of Ménière’s disease, especially in the control of vertigo.”¹

■ Restores vestibular responses

“In a preliminary trial (Wilmot 1971) using objective testing of both auditory and vestibular function . . . the results showed statistical significance in favour of Serc.”²

■ Reduced severity of episodic vertigo

“... a significant improvement in favour of the drug (Serc) with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom.”¹

■ Well tolerated

“No adverse reactions were observed.”¹

REFERENCES:

- 1 Frew, I.J.C. et al: Postgrad. Med. J.; 52:501-503, 1976.
- 2 Wilmot, T.J. et al: J. Laryng. Otol; 9:833-840, 1976.

PRESCRIBING INFORMATION:

INDICATIONS: SERC may be of value in reducing the episodes of vertigo in Meniere’s disease. No claim is made for the effectiveness of SERC in the symptomatic treatment of any form of vertigo other than that associated with Meniere’s disease.

DOSAGE AND ADMINISTRATION: The usual adult dosage has been one to two tablets (4 mg. each) administered orally three times a day.

Recommended starting dose is two tablets three times daily. Therapy is then adjusted as needed to maintain patient response. The dosage has ranged from two tablets per day to eight tablets per day. No more than eight tablets are recommended to be taken in any one day.

SERC (betahistine hydrochloride) is not recommended for use in children. As with all drugs, SERC should be kept out of reach of children.

CONTRAINDICATIONS: Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using SERC. Although no causal relation has been established SERC is contraindicated in the presence of peptic ulcer and in patients with a history of this condition. SERC is also contraindicated in patients with pheochromocytoma.

PRECAUTIONS: Although clinical intolerance to SERC by patients with bronchial asthma has not been demonstrated, caution should be exercised if the drug is used in these patients.

USE IN PREGNANCY: The safety of SERC in pregnancy has not been established. Therefore, its use in pregnancy or lactation, or in women of childbearing age requires that its potential benefits be weighed against the possible risks.

ADVERSE REACTIONS: Occasional patients have experienced gastric upset, nausea and headache.

HOW SUPPLIED: Scored tablets of 4 mg each in bottles of 100 tablets.

Full prescribing information available on request.

UNIMED

Canada Inc.

Dorval, Quebec H9P 2P4

PAAB
CCPP



Sandomigran® DS 1 mg
pizotiline
(Double Strength)

Brief Prescribing Information

Since vascular headache is a paroxysmal but basically chronic disorder, treatment must extend over an adequate period of time in order to obtain maximal benefit. While some patients have responded rather quickly, most investigators agree that a four-week trial period should be instituted to determine the true efficacy of pizotiline in specific cases. The periodic nature of the disorder will have to be considered in determining when and for how long therapy should be maintained. Since some investigators have observed a change in headache pattern after several months of therapy, a drug-free interval is advisable to reassess the necessity of continuing treatment. The dosage should be reduced gradually during the last two weeks of each treatment course to avoid a "headache rebound".

Contraindications: Anticholinergic agents, including pizotiline, are contraindicated in patients taking monoamine oxidase inhibitors, and in patients with pyloroduodenal obstruction and stenosing pyloric ulcer. Pizotiline is also contraindicated for patients who have a known sensitivity to the drug. Until further studies are completed, the drug is not recommended for children under the age of twelve.

Warnings and precautions: Since drowsiness may occur with pizotiline, sensitive patients should be cautioned against activities requiring rapid and precise response (i.e. driving an automobile or operating dangerous machinery) until their response to the drug has been determined. Since the effects of antihistamines can potentiate those of other drugs affecting the central nervous system, patients should be cautioned against drinking alcoholic beverages or taking hypnotics, sedatives, psychotherapeutic agents or other drugs with CNS depressant effects during pizotiline therapy. Administer pizotiline with caution to patients with narrow angle glaucoma or with urinary retention (e.g. prostatic hypertrophy).

Since it is desirable to keep drug administration to a minimum during pregnancy, pizotiline should be given only when the benefits derived from treatment exceed the possible risks to mother and fetus.

Some patients developed tolerance to pizotiline with prolonged use of the drug. An increase in dosage may overcome this tolerance.

After prolonged use, hepatotoxic effects might occur and patients should be advised to report for adequate laboratory evaluation.

Patients with diabetes, cardiovascular disease and known or suspected impaired renal or hepatic function should be given pizotiline with caution, and appropriate laboratory tests should be done at regular intervals.

Lens opacities occurred in two cases, but did not appear to be drug-related. However, it is recommended that any impairment in vision be reported to the attending physician for further investigation.

Dosage: Days 1-4: ½ DS tablet increasing to 1 DS tablet at bedtime. Days 5-28: increasing to between 1 and 2 DS tablets per day and, if necessary, gradually up to 6 DS tablets a day in divided doses.

Side effects: Increased appetite, weight gain, and drowsiness are the most frequent side effects. An appropriate diet should be recommended by the physician for patients benefiting from the drug but gaining excessive weight. A gradual increase in the dosage of pizotiline is recommended to minimize or reduce the incidence of drowsiness. The following adverse effects have been observed less frequently in relation to the aforementioned reactions: fatigue, nausea, dizziness, headache, confusion, edema, hypotension, depression, weakness, epigastric distress, dry mouth, nervousness, impotence and muscle pain.

Composition: Each single-scored white DS tablet contains 1 mg of pizotiline as the hydrogen malate.

Supplied 1 mg scored DS (Double Strength) tablets in bottles of 100.

Complete prescribing information available to physicians and pharmacists on request.


REFERENCES:

1. Sicuteri, F., et al., An antaminic drug, BC-105, in the prophylaxis of migraine. *Int. Arch. Allergy.*, 1967; 31:78-93.
2. Schaer, J., BC-105, A new serotonin antagonist in the treatment of migraine. *Headache*, 1970; 10:67-73.
3. Schaer, J., Experience with BC-105 in the treatment of migraine. In: *Proceedings of the Int. Headache Symposium*, Elsinore, Denmark, Dalessio, D. et al. (eds.), Basel, Switzerland, Sandoz Inc. The American Association for the Study of Headache and The Danish Migraine Society, 1971; 185-187.
4. Behan, P.O., Pizotifen in the treatment of severe recurrent headache, Single and divided dose therapy compared, *Brit. J. Clin. P. Pract.*, 1982; 36:13-17.

SANDOMIGRAN DS MAINTENANCE THERAPY HELPS PREVENT RECURRING HEADACHES

Taken daily for at least four weeks, Sandomigran DS can prevent, not relieve recurring headaches.

Sandomigran can reduce the frequency, severity and duration of vascular or mixed headaches^{1, 2}. For many patients, Sandomigran has stopped throbbing headaches altogether^{2, 3}.



DOUBLE STRENGTH DS TABLETS IMPROVE COMPLIANCE.

With fewer tablets to take, patients find it easier to comply with maintenance therapy. With a half-life of 23 hours⁴, treatment can be initiated H.S. And dosage may be increased, up to six D.S. tablets in divided doses per day. (See prescribing information).

Sandomigran® DS 1 mg
(pizotiline)

SANDOZ
▲▲▲

Sandoz Canada Inc.
Dorval, Québec H9R 4P5

SANDOZ®

Sandoz Canada Inc.
Dorval, Québec H9R 4P5

PAAB
CCPF

**Some drugs
are just too important
to allow substitution**

Tegretol[®]

Carbamazepine

**The original carbamazepine
for the treatment of epilepsy.
Because there is no substitute
for experience.
Yours or Ours.**



Geigy

Mississauga, Ontario
L5N 2W5

PAAB
CCPP